|
|||||
|
|
Frailty Intervention Trial (FIT) |
|
| Authors: | Nicola Fairhall Christina Aggar Susan E Kurrle Catherine Sherrington Stephen Lord Keri Lockwood Noeline Monaghan Ian D Cameron |
| Affiliation: | 1. The Australian National University, Canberra, Australia 2. The University of Melbourne, Melbourne, Australia 3. School of Psychiatry, University of New South Wales, Sydney, Australia 4. Neuropsychiatric Institute, the Prince of Wales Hospital, Sydney, Australia |
| Abstract: | BackgroundWhile the evidence of an association between the apolipoprotein E (APOE) *E4 allele and Alzheimer's disease is very strong, the effect of the *E4 allele on cognitive decline in the general population is more equivocal. A cross-sectional study on the lifespan effects of the *E4 allele [1] failed to find any effect of the *E4 allele on cognitive performance at ages 20–24, 40–44 or 60–64 years.MethodsIn this four year follow-up study, we reexamine the effect of *E4 in the sample of 2,021 individuals, now aged 65–69 years.ResultsPerformance on the Mini-Mental State Examination (MMSE) was significantly poorer for *E4 homozygotes than heterozygotes or non-carriers. The effects of the *E4 genotype on cognitive decline over four years were found on the MMSE and Symbol-Digit Modalities test but only when controlling for risk factors such as head injury and education. Analyses were repeated with the exclusion of participants diagnosed with a mild cognitive disorder, with little change.ConclusionIt is possible that *E4 carriers become vulnerable to greater cognitive decline in the presence of other risk factors at 65–69 years of age. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |